FDA finds safety concerns with J&J attention-deficit drug

Share this article:
The FDA has identified a set of possible safety concerns with Johnson & Johnson's attention-deficit disorder drug Concerta, the agency said in a statement posted on its Web site yesterday.
A panel of FDA advisors is scheduled to discuss post-marketing reports of hallucinations, psychotic behavior, suicidal thoughts and heart complications such as high blood pressure at a meeting in Rockville, Md. tomorrow.
Concerta is a once-daily form of Novartis' Ritalin and the most prescribed drug for attention deficit hyperactivity disorder (ADHD), according to a Johnson & Johnson Web site.
Last year, the FDA gave doctors warnings about sudden cardiovascular death linked to another ADHD drug, Shire's Adderall. Canadian health officials in February ordered Adderall to be withdrawn from the market after it was linked to at least 20 deaths.
A Johnson & Johnson spokeswoman said in published reports that the company would not discuss the FDA's statement ahead of Thursday's meeting.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...